CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

Rhea-AI Summary

CorMedix (Nasdaq: CRMD) announced its participation in the Truist Securities BioPharma Symposium scheduled for November 7, 2024, in New York City. The event will feature one-on-one meetings at the Lotte New York Palace Hotel. CorMedix is focused on commercializing DefenCath®, their lead product approved by the FDA in November 2023. The company has already launched DefenCath in inpatient settings in April 2024 and expanded to outpatient settings in July 2024. They plan to further develop DefenCath as a catheter lock solution for additional patient populations.

News Market Reaction – CRMD

-4.00%

-4.00% Session move

In the trading session that priced this news, CRMD declined 4.00%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the Truist Securities BioPharma Symposium, taking place in New York City on Thursday, November 7, 2024.

Truist Securities BioPharma Symposium
Date:	Thursday, November 7, 2024
Format:	1x1 meetings
Location:	Lotte New York Palace Hotel, New York, NY

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath^®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

FAQ

When did CorMedix (CRMD) launch DefenCath in outpatient settings?

CorMedix launched DefenCath in outpatient settings in July 2024.

What event is CorMedix (CRMD) participating in on November 7, 2024?

CorMedix is participating in the Truist Securities BioPharma Symposium in New York City.

When did the FDA approve DefenCath for CorMedix (CRMD)?

The FDA approved DefenCath on November 15, 2023.

When did CorMedix (CRMD) first launch DefenCath in inpatient settings?

CorMedix launched DefenCath in inpatient settings in April 2024.